Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Clinical trial NCT06234397 · RECRUITING
Trial details
- NCT number
- NCT06234397
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-28
- Primary completion
- 2027-08-01
- Enrollment
- 245
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.